(Q44136600)

English

HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes

scientific article published in October 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes (English)

1 reference

Europe PubMed Central

30 November 2017

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

30 November 2017

author name string

Akimitsu Takahashi

2

1 reference

Europe PubMed Central

30 November 2017

Hitoshi Shimano

3

1 reference

Europe PubMed Central

30 November 2017

Shun Ishibashi

4

1 reference

Europe PubMed Central

30 November 2017

Gen Yoshino

5

1 reference

Europe PubMed Central

30 November 2017

Nobuhiro Morisaki

6

1 reference

Europe PubMed Central

30 November 2017

Yasushi Saito

7

1 reference

Europe PubMed Central

30 November 2017

Shoji Kawazu

8

1 reference

Europe PubMed Central

30 November 2017

Tamio Teramoto

9

1 reference

Europe PubMed Central

30 November 2017

Toshiro Fujita

10

1 reference

Europe PubMed Central

30 November 2017

Teruo Shiba

11

1 reference

Europe PubMed Central

30 November 2017

Yasuhiko Iwamoto

12

1 reference

Europe PubMed Central

30 November 2017

Nobuaki Kuzuya

13

1 reference

Europe PubMed Central

30 November 2017

Yasuo Akanuma

14

1 reference

Europe PubMed Central

30 November 2017

Nobuhiro Yamada

15

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

1 October 2002

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

71

1 reference

Europe PubMed Central

30 November 2017

20

1 reference

Europe PubMed Central

30 November 2017

2403-2412

1 reference

Europe PubMed Central

30 November 2017

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Diabetic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Relationship of LDL size to insulin sensitivity in normoglycemic men.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Small dense low-density lipoprotein in Japanese men with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Influence of 4 weeks' intervention by exercise and diet on low-density lipoprotein subfractions in obese men with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2802%2902038-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0024-3205(02)02038-6

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44136600&oldid=2106988645"